Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20558774 | 1.00 | L3MBTL1 (0.48) | L3MBTL1FFAR4KMT2AMEN1NPC1 | |
| SCHEMBL20788551 | 0.84 | FFAR4 (0.63) | FFAR4GRM2MRGPRX4 | |
| SCHEMBL20559634 | 0.84 | FFAR4 (0.63) | FFAR4GRM2MRGPRX4 | |
| SCHEMBL20559109 | 0.76 | FFAR4 (0.51) | FFAR4 | |
| SCHEMBL20559110 | 0.76 | FFAR4 (0.51) | FFAR4 | |
| SCHEMBL1011144 | 0.76 | SLC18A2 (0.50) | KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL15805066 | 0.76 | SLC18A2 (0.50) | KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL15805101 | 0.76 | SLC18A2 (0.50) | KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL15797739 | 0.76 | SLC18A2 (0.50) | KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL9811728 | 0.75 | KDM4E (0.60) | L3MBTL1KMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-08-23 | — | — | US | disclosed |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3404021-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2018-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | CACNA1I, CACNA1G, CACNA1E | L3MBTL1 1700/4885FFAR4 2440/4885KMT2A 1735/4885 |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1E | L3MBTL1 1375/4885FFAR4 2162/4885KMT2A 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.